Eli Lilly's Pipeline Unveiled & LLY Stock Analysis Breakdown

TL;DR

Eli Lilly, a pharmaceutical company, has shown consistent profits but raises concerns with lower free cash flow compared to net income. With a high PE ratio and a small dividend payout, the company has strong gross margins but faces challenges in maintaining a profitable pipeline. Analyst estimates project significant earnings growth, but the stock may be overpriced.

Transcript

Eli Lilly is up 48 this year 430 percent in the last five years they pay a small dividend so that doesn't even include their dividend let's check it out in this video guys there's something for beginners or something for more advanced we cover the whole Gambit we're gonna go over the overall metrics of the company we're going to go over the eight p... Read More

Key Insights

• 💐 Eli Lilly has shown consistent profits but raises concerns with lower free cash flow compared to net income, potentially indicating financial strain.
• 🥳 The company's high PE ratio suggests the stock may be overpriced, requiring significant future growth to justify its current valuation.
• ❓ The pipeline of marketable drugs is crucial for sustained revenue growth in the pharmaceutical industry, as patents eventually expire and revenue declines.
• 🎯 Analyst projections for Eli Lilly's earnings per share indicate significant growth, but achieving these targets may be challenging.
• 💄 Investors should carefully evaluate the company's financials and consider the risks involved before making an investment decision.
• 🧑‍🏭 The EverythingMoney software provides tools to analyze investments and helps investors make informed decisions based on a combination of financial metrics and qualitative factors.
• ⚾ While Eli Lilly may not be an attractive investment based on the current analysis, individual investors may have different perspectives and insights.

Questions & Answers

Q: What are analysts' projections for Eli Lilly's earnings per share?

Analysts expect the company to make $8.79 per share, with projected earnings of $21.47 per share in four years. These estimates suggest significant growth, but may be difficult to achieve given the current stock price.

Q: What are the key concerns regarding Eli Lilly's financials?

One concern is the company's lower free cash flow compared to net income, which raises questions about its ability to afford dividends. Additionally, the high PE ratio suggests the stock may be overpriced.

Q: How important is the pipeline of drugs for pharmaceutical companies like Eli Lilly?

The pipeline is crucial for sustained revenue growth, as patents on drugs eventually expire, leading to a decline in revenue. However, it is important that the drugs in the pipeline are marketable and able to generate significant profits.

Q: Should investors consider Eli Lilly a good investment?

It depends on individual analysis and risk tolerance. While Eli Lilly has strong gross margins and analyst expectations for growth, the stock may be overpriced considering the challenges faced by the company in maintaining profitability and developing a profitable drug pipeline.

Summary & Key Takeaways

• Eli Lilly has a market cap of $486 billion and has shown consistent profits, generating $30 billion in revenue and $6.5 billion in profit in the last year.

• Concerns arise with the company's lower free cash flow compared to net income, indicating potential financial strain.

• With a high PE ratio of 75 and a small dividend yield, Eli Lilly faces challenges in maintaining profitability and justifying its current stock price.